TPMT/NUDT15 genotyping (thiopurine toxicity panel)

Description: 
TPMT deficiency due to presence of genetic sequence variants is associated with toxicity to thiopurine drug therapies. Variants in the NUDT15 gene have also been associated with thiopurine-induced myelosuppression. The Purine Research Laboratory in Biochemical Sciences offers a thiopurine toxicity panel consisting of four TPMT sequence variants and one variant in the NUDT15 gene. Real time PCR based methods are used to genotype patients for the TPMT*3C, TPMT*3B, TPMT*2 and NUDT15*3 variants, prior to the start of thiopurine therapy.
Clinical details: 
Clinical indications for TPMT/NUDT15 genotyping:
- Children and young adults with acute lymphoblastic leukaemia about to be treated with mercaptopurine.
- Patients who have received a blood transfusion within the last 3 months as this may falsely raise TPMT enzyme activity.
- Patients on renal failure/renal transplant/dialysis. TPMT inhibitors may accumulate in the blood of patients in renal failure.
- Patients with very low Hb (Hb≤70g/L). Correlation between TPMT genotype and phenotype is poor for these patients.

Sample type and Volume required: 
4 mL blood EDTA (purple top)
Turnaround time: 
3 days
Special sample instructions: 

Thiopurine toxicity panel:

Allele               c.DNA              Amino acid           rs number
TPMT*2          c.238G>C       p.(Ala80Pro)         rs1800462
TPMT*3B       c.460G>A        p.(Ala154Thr)       rs1800460
TPMT*3C       c.719A>G        p.(Tyr240Cys)       rs1142345
NUDT15*3     c.415C>T        p.(Arg139Cys)       rs766023281

Storage and transport: 
Store in fridge, ( don’t freeze) to laboratory within 3 days/1st class post
Contacts:
Purine Research Laboratory at St Thomas'
020 7188 1266
St Thomas’ Hospital
North Wing - 4th Floor
Westminster Bridge Road
London SE1 7EH
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 24/02/2023